Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > ----------MAY 5TH $1,400,000 IN THE BANK--

<< Previous

Bullboard Posts

Next >>

Comment by 90guppyon Jun 11, 2020 8:25am

102 Views

Post# 31137588

RE:----------MAY 5TH $1,400,000 IN THE BANK--

yes, but you are missing this " In our PR regarding the collaboration agreement with the hospital we indicated that we had sufficient funds for that work. However we require additional funds to pursue other patents that we would like develop in order to create shareholder value".

I can see what it is and that is what I am waiting for